Neutrophil-Lymphocyte Ratio as a Predictive Factor of Growing Malignant Pulmonary Ground-glass Opacity.
early lung adenocarcinoma
ground-glass opacity
neutrophil–lymphocyte ratio
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
05
2021
accepted:
22
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
The object of the study was to elucidate the relationship between the neutrophil-lymphocyte ratio (NLR) and the growth of pulmonary ground-glass opacity (GGO) in stage IA lung adenocarcinoma. All patients with GGO following surgical procedures were enrolled, with the time of follow-up and the variation tendency of GGO recorded. Meanwhile, laboratory parameters, age, gender, smoking history, histology, tumor size, and stage were recorded. Logistic regression was used to evaluate the value of NLR and the cutoff value was calculated by SPSS 22.0. In the whole cohort, 30 cases of growing GGO and 43 cases of stable GGO undergoing surgical procedures were diagnosed as lung adenocarcinoma. There was significant statistical difference between the two groups. Multivariable analysis showed that NLR could predict the GGOs with growth (odds ratio 5.198, 95% confidence interval (95%CI: 1.583-14.581, Our study demonstrated that the NLR appeared to have value as a promising clinical predictor of GGOs with growth. Further studies are needed to confirm this conclusion.
Sections du résumé
BACKGROUND
BACKGROUND
The object of the study was to elucidate the relationship between the neutrophil-lymphocyte ratio (NLR) and the growth of pulmonary ground-glass opacity (GGO) in stage IA lung adenocarcinoma.
METHODS
METHODS
All patients with GGO following surgical procedures were enrolled, with the time of follow-up and the variation tendency of GGO recorded. Meanwhile, laboratory parameters, age, gender, smoking history, histology, tumor size, and stage were recorded. Logistic regression was used to evaluate the value of NLR and the cutoff value was calculated by SPSS 22.0.
RESULTS
RESULTS
In the whole cohort, 30 cases of growing GGO and 43 cases of stable GGO undergoing surgical procedures were diagnosed as lung adenocarcinoma. There was significant statistical difference between the two groups. Multivariable analysis showed that NLR could predict the GGOs with growth (odds ratio 5.198, 95% confidence interval (95%CI: 1.583-14.581,
CONCLUSION
CONCLUSIONS
Our study demonstrated that the NLR appeared to have value as a promising clinical predictor of GGOs with growth. Further studies are needed to confirm this conclusion.
Identifiants
pubmed: 34285585
doi: 10.2147/CMAR.S319190
pii: 319190
pmc: PMC8286107
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5651-5655Informations de copyright
© 2021 Xue et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
Ann Thorac Surg. 2009 Feb;87(2):365-71; discussion 371-2
pubmed: 19161739
J Hepatol. 2013 Jan;58(1):58-64
pubmed: 22925812
Radiology. 2011 Jan;258(1):243-53
pubmed: 21045183
Lung Cancer. 2009 May;64(2):171-8
pubmed: 18799230
Biomarkers. 2012 May;17(3):216-22
pubmed: 22424597
Ann Thorac Surg. 2017 Jul;104(1):313-320
pubmed: 28433219
Am J Pathol. 1998 Jan;152(1):83-92
pubmed: 9422526
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Cancer Imaging. 2013 Sep 23;13(3):365-73
pubmed: 24061063
Ann Surg. 2013 Aug;258(2):301-5
pubmed: 23774313
Am J Surg. 2010 Aug;200(2):197-203
pubmed: 20122680
Med Res Rev. 2011 May;31(3):311-63
pubmed: 19967776
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Ann Surg Oncol. 2011 Nov;18(12):3362-9
pubmed: 21547702
Angiogenesis. 2003;6(4):283-7
pubmed: 15166496
Br J Cancer. 2012 Nov 6;107(10):1729-36
pubmed: 23059742
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Curr Top Microbiol Immunol. 2011;344:1-24
pubmed: 20512556
J Thorac Cardiovasc Surg. 2002 Aug;124(2):278-84
pubmed: 12167787
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787